Larimar Therapeutics (LRMR) 10-Q 5 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	ZFGN
Entity Registrant Name	Zafgen, Inc.
Entity Central Index Key	1,374,690
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		27,329,233

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 20,026	$ 35,595
Marketable securities	130,442	149,484
Tax incentive receivable	1,350	1,323
Prepaid expenses and other current assets	1,334	1,708
Total current assets	153,152	188,110
Tax incentive receivable	331
Property and equipment, net	1,256	902
Other assets	87	94
Total assets	154,826	189,106
Current liabilities:
Accounts payable	2,581	7,495
Accrued expenses	4,976	6,112
Notes payable, current	3,057	2,936
Total current liabilities	10,614	16,543
Notes payable, net of discount, long-term	1,973	3,453
Total liabilities	12,587	19,996
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of June 30, 2016 and December 31, 2015; no shares issued and outstanding as of June 30, 2016 and December 31, 2015
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of June 30, 2016 and December 31, 2015; 27,272,261 and 27,242,503 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	27	27
Additional paid-in capital	354,661	348,961
Accumulated deficit	(212,435)	(179,671)
Accumulated other comprehensive loss	(14)	(207)
Total stockholders' equity	142,239	169,110
Total liabilities and stockholders' equity	$ 154,826	$ 189,106

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	115,000,000	115,000,000
Common stock, shares issued	27,272,261	27,242,503
Common stock, shares outstanding	27,272,261	27,242,503

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	10,163	12,526	22,660	22,741
General and administrative	4,899	5,084	10,259	8,109
Total operating expenses	15,062	17,610	32,919	30,850
Loss from operations	(15,062)	(17,610)	(32,919)	(30,850)
Other income (expense):
Interest income	225	63	434	102
Interest expense	(140)	(213)	(300)	(426)
Foreign currency transaction gains (losses), net	(51)	4	21	(54)
Total other income (expense), net	34	(146)	155	(378)
Net loss	$ (15,028)	$ (17,756)	$ (32,764)	$ (31,228)
Net loss per share, basic and diluted	$ (0.55)	$ (0.66)	$ (1.20)	$ (1.19)
Weighted average common shares outstanding, basic and diluted	27,272,225	27,011,960	27,267,830	26,316,619
Comprehensive loss:
Net loss	$ (15,028)	$ (17,756)	$ (32,764)	$ (31,228)
Other comprehensive gain (loss):
Unrealized gain (loss) on marketable securities	(15)	(21)	193	(25)
Total other comprehensive gain (loss)	(15)	(21)	193	(25)
Total comprehensive loss	$ (15,043)	$ (17,777)	$ (32,571)	$ (31,253)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (32,764)	$ (31,228)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	5,610	2,996
Non-cash interest expense	24	33
Depreciation expense	102	14
Unrealized foreign currency transaction (gains) losses	(108)	38
Premium on marketable securities, net	(233)	(675)
Amortization of premium on marketable securities	715	377
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	374	202
Tax incentive receivable	(250)	(687)
Accounts payable	(4,710)	2,014
Accrued expenses	(1,039)	1,442
Net cash used in operating activities	(32,279)	(25,474)
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	88,660	79,717
Purchases of marketable securities	(69,907)	(158,632)
Purchases of property and equipment	(660)	(150)
Net cash provided by (used in) investing activities	18,093	(79,065)
Cash flows from financing activities:
Repayments of notes payable	(1,438)
Proceeds from exercise of common stock options and employee stock purchase plan	55	438
Proceeds from public offerings, net of commissions and underwriting discounts		130,044
Payments of public offering costs		(473)
Net cash (used in) provided by financing activities	(1,383)	130,009
Net (decrease) increase in cash and cash equivalents	(15,569)	25,470
Cash and cash equivalents at beginning of period	35,595	58,103
Cash and cash equivalents at end of period	20,026	83,573
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment included in accounts payable	204
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 224	$ 304

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation Zafgen, Inc., or the Company, was incorporated on November 22, 2005 under the laws of the State of Delaware. The Company is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company is focused on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. The Company has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. The Company’s lead product candidate is ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of severe and complicated types of obesity. The Company is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity. Since its inception, the Company has devoted substantially all of its efforts to research and development, recruiting management, acquiring operating assets and raising capital. On July 19, 2016, the Company announced that it was refocusing its resources on the development of ZGN-1061 and suspending further development of beloranib, an earlier generation MetAP2 inhibitor, that it had been developing as a treatment for obesity and hyperphagia in Prader-Willi syndrome, or PWS, and for hypothalamic injury associated obesity, or HIAO. The beloranib Investigational New Drug application, or IND, was placed on full clinical hold in December 2015 by the FDA, as a result of an imbalance in the number of thrombotic events observed in patients treated with beloranib as compared to patients on placebo in the Company’s clinical trials. To address the full clinical hold, the Company held a Type A meeting with the FDA in June 2016 to discuss the clinical and pre-clinical data for beloranib, as well as a proposed risk mitigation strategy for beloranib in PWS. Following its discussions with the FDA, a comprehensive review of the Company’s assets and clinical programs, and review of other considerations, the Company determined that the obstacles, costs and development timelines to obtain marketing approval for beloranib were too great to justify additional investment in the program, particularly given the promising emerging profile of ZGN-1061. In connection with its corporate refocusing, the Company also announced that its workforce is being reduced by approximately 34%, to a total of 31 employees, by December 2016. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. The Company’s product candidates are all in the development stage. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any product candidates developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Zafgen Securities Corporation, Zafgen Australia Pty Limited, and Zafgen Animal Health, LLC. All intercompany balances and transactions have been eliminated. On January 28, 2015, the Company completed a follow-on offering of its common stock, which resulted in the sale of 3,942,200 shares at a price of $35.00 per share. The Company received net proceeds from the follow-on offering of $130.0 million based upon the price of $35.00 per share after deducting underwriting discounts and commissions paid by the Company. The Company also incurred offering costs of $0.5 million related to the follow-on offering. Unaudited Interim Financial Information The condensed consolidated balance sheet as of December 31, 2015 was derived from the Company’s audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America, or GAAP. The accompanying unaudited condensed consolidated financial statements as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2015, on file with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of June 30, 2016 and condensed consolidated results of operations and cash flows for the three and six months ended June 30, 2016 and 2015 have been made. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates. Marketable securities Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices. Net Income (Loss) Per Share Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company excluded the following common stock equivalents, outstanding as of June 30, 2016 and 2015, from the computation of diluted net loss per share for the three and six months ended June 30, 2016 and 2015 because they had an anti-dilutive impact due to the net loss incurred for the periods: As of June 30, 2016 2015 Options to purchase common stock 3,976,995 2,500,741 Unvested restricted common stock units 9,955 2,903 3,986,950 2,503,644 Recently Issued and Adopted Accounting Pronouncements In August 2014, the Financial Accounting Standards Board, or FASB, issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting

Fair Value Measurements and Mar

Fair Value Measurements and Marketable Securities	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements and Marketable Securities	3. Fair Value Measurements and Marketable Securities Fair Value Measurements The following tables present information about the Company’s financial assets that have been measured at fair value as of June 30, 2016 and December 31, 2015, and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The following tables summarize the Company’s cash equivalents and marketable securities as of June 30, 2016 and December 31, 2015: June 30, 2016 Quoted Significant Prices in Other Significant Active Observable Unobservable Markets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents: Money market funds $ 13,909 $ 13,909 $ — $ — Total cash equivalents 13,909 13,909 — — Marketable securities: Corporate bonds 95,959 — 95,959 — Commercial paper 25,194 — 25,194 — U.S. government securities 9,289 — 9,289 — Total marketable securities 130,442 — 130,442 — Total cash equivalents and marketable securities $ 144,351 $ 13,909 $ 130,442 $ — December 31, 2015 Quoted Significant Prices in Other Significant Active Observable Unobservable Markets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents: Money market funds $ 13,231 $ 13,231 $ — $ — U.S. government securities 4,999 — 4,999 — Commercial paper 4,697 — 4,697 — Corporate bonds 3,000 — 3,000 — Total cash equivalents 25,927 13,231 12,696 — Marketable securities: Corporate bonds 125,516 — 125,516 — Commercial paper 19,468 — 19,468 — U.S. government securities 4,500 — 4,500 — Total marketable securities 149,484 — 149,484 — Total cash equivalents and marketable securities $ 175,411 $ 13,231 $ 162,180 $ — The carrying amounts reflected in the condensed consolidated balance sheets for tax incentive receivable, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. The carrying value of the Company’s outstanding notes payable approximates fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. Marketable Securities The following tables summarize the Company’s marketable securities as of June 30, 2016 and December 31, 2015: June 30, 2016 Gross Gross Amortized Unrealized Unrealized Cost Gains Losses Fair Value (in thousands) Assets: Corporate bonds (due within 1 year) $ 94,651 $ 19 $ (33 ) $ 94,637 Corporate bonds (due after 1 year through 2 years) 1,317 5 — 1,322 Commercial paper (due within 1 year) 25,199 1 (6 ) 25,194 U.S. government securities (due within 1 year) 9,289 — — 9,289 $ 130,456 $ 25 $ (39 ) $ 130,442 December 31, 2015 Gross Gross Amortized Unrealized Unrealized Cost Gains Losses Fair Value (in thousands) Assets: Corporate bonds (due within 1 year) $ 112,825 $ 1 $ (166 ) $ 112,660 Corporate bonds (due after 1 year through 2 years) 12,884 3 (31 ) 12,856 Commercial paper (due within 1 year) 19,478 — (10 ) 19,468 U.S. government securities (due within 1 year) 4,500 — — 4,500 $ 149,687 $ 4 $ (207 ) $ 149,484

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses Accrued expenses consisted of the following as of June 30, 2016 and December 31, 2015: June 30, December 31, 2016 2015 (in thousands) Accrued research and development expenses $ 3,082 $ 3,727 Accrued payroll and related expenses 1,299 1,802 Accrued professional fees 484 422 Accrued other 111 161 $ 4,976 $ 6,112

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable The Company has outstanding amounts due under a loan and security agreement with Oxford Finance LLC and Midcap Financial, or the 2014 Credit Facility, entered into in March 2014. All promissory notes issued under the 2014 Credit Facility are collateralized by substantially all of the Company’s personal property, other than its intellectual property. There are no financial covenants associated with the 2014 Credit Facility; however, there are negative covenants restricting the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering or granting a security interest in its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and certain other business transactions. As of June 30, 2016 and December 31, 2015, notes payable consist of the following: June 30, December 31, 2016 2015 (in thousands) Notes payable $ 4,680 $ 6,119 Less: current portion (3,057 ) (2,936 ) Notes payable, net of current portion 1,623 3,183 Debt discount, net of accretion (20 ) (36 ) Accretion related to final payment 370 306 Notes payable, net of discount, long term $ 1,973 $ 3,453 As of June 30, 2016, the estimated future principal payments due are as follows: Years Ending December 31, (in thousands) 2016 (July to December) $ 1,497 2017 3,183 Total $ 4,680 During the three months ended June 30, 2016 and 2015, the Company recognized $0.1 million and $0.2 million, respectively, of interest expense related to the 2014 Credit Facility. During the six months ended June 30, 2016 and 2015, the Company recognized $0.3 million and $0.4 million, respectively, of interest expense related to the 2014 Credit Facility. The effective annual interest rate of the outstanding debt under the 2014 Credit Facility is approximately 10.8%.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity On January 28, 2015, the Company completed a follow-on offering of its common stock, which resulted in the sale of 3,942,200 shares at a price of $35.00 per share. The Company received net proceeds from the follow-on offering of $130.0 million based upon the price of $35.00 per share after deducting underwriting discounts and commissions paid by the Company. The Company also incurred offering costs of $0.5 million related to the follow-on offering.

Stock-Based Awards

Stock-Based Awards	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Awards	7. Stock-Based Awards The Company grants equity awards under its 2014 Stock Option and Incentive Plan, or the 2014 Stock Option Plan, and is authorized to issue common stock under its 2014 Employee Stock Purchase Plan. The Company also has outstanding stock-based awards under its Amended and Restated 2006 Stock Option Plan but is no longer granting awards under this plan. As of June 30, 2016, 1,270,303 shares are available for grant under the 2014 Stock Option Plan, including 1,089,700 shares automatically added to the 2014 Stock Option Plan on January 1, 2016 as a result of a provision in the 2014 Stock Option Plan. The Company recorded stock-based compensation expense related to stock options and restricted common stock in the following expense categories within its consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (in thousands) (in thousands) Research and development $ 1,002 $ 738 $ 1,830 $ 1,142 General and administrative 1,852 1,201 3,780 1,854 $ 2,854 $ 1,939 $ 5,610 $ 2,996 As of June 30, 2016, there were outstanding unvested service-based stock options held by nonemployees for the purchase of 9,590 shares of common stock.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Leases The Company has a lease for office space in Boston, Massachusetts, effective as of July 28, 2014, with a term expiring July 31, 2017 and an option to extend the lease for three additional years. In March 2015, the Company entered into an operating lease for additional office space in Boston, Massachusetts, effective as of April 15, 2015, with a term expiring on July 31, 2017, and two options to extend this lease for three additional years each. In October 2015, the Company entered into an operating lease for office space in San Diego, California, effective as of October 1, 2015, with a term expiring on September 30, 2019, and an option to extend this lease for five additional years. Future minimum lease payments for its operating leases as of June 30, 2016 were as follows: Years Ending December 31, (in thousands) 2016 (July - December) $ 219 2017 300 2018 106 2019 82 $ 707 During the three months ended June 30, 2016 and 2015, the Company recognized $0.1 million of rental expense related to office space. During the six months ended June 30, 2016 and 2015, the Company recognized $0.2 million and $0.1 million, respectively, of rental expense related to office space. Intellectual Property Licenses The Company has acquired exclusive rights to develop patented compounds and related know-how for beloranib under two licensing agreements with two third parties in the course of its research and development activities. The licensing rights obligate the Company to make payments to the licensors for license fees, milestones, license maintenance fees and royalties. The Company is also responsible for patent prosecution costs. As of June 30, 2016, the Company is obligated to make additional milestone payments of up to $12.3 million upon reaching certain pre-commercialization milestones, such as clinical trials and government approvals (including the U.S. Food and Drug Administration, or FDA, approval of a New Drug Application, or NDA), and up to $12.5 million upon reaching certain product commercialization milestones related to the development of beloranib. Under one of the license agreements, the Company is also obligated to pay up to $1.3 million with respect to each subsequent licensed product, if any, that is a new chemical entity. In addition, the Company will owe single-digit royalties on sales of commercial products developed using these licensed technologies, if any. There were no milestones achieved during the three and six months ended June 30, 2016 or 2015. The Company is also obligated to pay to the licensors a percentage of fees received if and when the Company sublicenses the technology. As of June 30, 2016, the Company has not yet developed a commercial product using the licensed technologies and it has not entered into any sublicense agreements for the technologies. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of management team and the Board of Directors of the Company, or Board of Directors, that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2016. Legal Proceedings The Company accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that the Company can reasonably estimate the amount of the loss. The Company reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and the views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in the Company’s accrued liabilities would be recorded in the period in which such determination is made. In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, the Company will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. The Company expenses legal costs as they are incurred. On October 21, 2015, a purported stockholder of the Company filed a putative class action lawsuit in the U.S. District Court for the District of Massachusetts, against the Company and Thomas E. Hughes, captioned Aviad Bessler v. Zafgen, Inc. and Thomas E. Hughes, No. 1:15-cv-13618. An amended complaint was filed on February 22, 2016. The amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 based on allegedly false and misleading statements and omissions regarding the Company’s clinical trials for its drug beloranib. The lawsuit seeks, among other things, unspecified compensatory damages in connection with the Company’s allegedly inflated stock price between June 19, 2014 and October 16, 2015, as a result of those allegedly false and misleading statements, as well as punitive damages, interest, attorneys’ fees and costs. On April 7, 2016, the Company filed a motion to dismiss the amended complaint. The Company is unable to predict the ultimate outcome of this action and therefore cannot estimate possible losses or ranges of losses, if any. The Company may periodically become subject to other legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused. Other than the above action, the Company is not aware of any other material claims as of June 30, 2016.

Retirement Plan

Retirement Plan	6 Months Ended
	Jun. 30, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement Plan	9. Retirement Plan The Company has a Savings Incentive Match Plan, or SIMPLE IRA, for employees. Under the terms of the plan, the Company contributes 2% of an employee’s annual base salary, up to a maximum of the annual Internal Revenue Service compensation limits, for all full-time employees. During the three months ended June 30, 2016 and 2015, the Company recognized less than $0.1 million of expense related to its contributions to the plan. During the six months ended June 30, 2016 and 2015, the Company recognized $0.1 million of expense related to its contributions to the plan.

Australia Research and Developm

Australia Research and Development Tax Incentive	6 Months Ended
	Jun. 30, 2016
Research and Development [Abstract]
Australia Research and Development Tax Incentive	10. Australia Research and Development Tax Incentive The Company’s wholly owned subsidiary, Zafgen Australia Pty Limited, which conducts core research and development activities on behalf of the Company, is eligible to receive a 45% refundable tax incentive for qualified research and development activities. For the three months ended June 30, 2016 and 2015, $0.2 million and $0.4 million, respectively, was recorded as a reduction to research and development expenses in the condensed consolidated statements of operations. For the six months ended June 30, 2016 and 2015, $0.3 million and $0.7 million, respectively, was recorded as a reduction to research and development expenses in the condensed consolidated statements of operations. These amounts represented 45% of the Company’s qualified research and development spending in Australia. The refund is denominated in Australian dollars and, therefore, the related receivable is re-measured into U.S. dollars as of each reporting date. For the three months ended June 30, 2016 and 2015, the Company recorded in its condensed consolidated statements of operations unrealized foreign currency exchange losses of less than $0.1 million related to this tax incentive receivable. For the six months ended June 30, 2016 and 2015, the Company recorded in its condensed consolidated statements of operations unrealized foreign currency exchange gains of less than $0.1 million and unrealized foreign currency exchange losses of less than $0.1 million, respectively, related to this tax incentive receivable. As of June 30, 2016 and December 31, 2015, the Company’s tax incentive receivable from the Australian government was $1.7 million and $1.3 million, respectively.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Event	11. Subsequent Event On July 19, 2016, the Company announced that following a comprehensive review of its assets and clinical programs, as well as feedback from regulatory authorities, the Company is refocusing its resources on development of a differentiated second-generation MetAP2 inhibitor, ZGN-1061. As part of the strategic restructuring, the Company has reorganized its operations to align with its new priorities focused on ZGN-1061 development. The Company’s workforce is being reduced by approximately 34%, to a total of 31 employees, by December 2016. The Company estimates there will be one-time charges related to the restructuring of approximately $2.4 million, the majority of which will be incurred in the third quarter of 2016.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.
Marketable securities	Marketable securities Marketable securities consist of investments with original maturities greater than ninety days. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company excluded the following common stock equivalents, outstanding as of June 30, 2016 and 2015, from the computation of diluted net loss per share for the three and six months ended June 30, 2016 and 2015 because they had an anti-dilutive impact due to the net loss incurred for the periods: As of June 30, 2016 2015 Options to purchase common stock 3,976,995 2,500,741 Unvested restricted common stock units 9,955 2,903 3,986,950 2,503,644
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements In August 2014, the Financial Accounting Standards Board, or FASB, issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Common Stock Equivalents Outstanding	The Company excluded the following common stock equivalents, outstanding as of June 30, 2016 and 2015, from the computation of diluted net loss per share for the three and six months ended June 30, 2016 and 2015 because they had an anti-dilutive impact due to the net loss incurred for the periods: As of June 30, 2016 2015 Options to purchase common stock 3,976,995 2,500,741 Unvested restricted common stock units 9,955 2,903 3,986,950 2,503,644

Fair Value Measurements and M19

Fair Value Measurements and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Cash Equivalents and Marketable Securities	The following tables summarize the Company’s cash equivalents and marketable securities as of June 30, 2016 and December 31, 2015: June 30, 2016 Quoted Significant Prices in Other Significant Active Observable Unobservable Markets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents: Money market funds $ 13,909 $ 13,909 $ — $ — Total cash equivalents 13,909 13,909 — — Marketable securities: Corporate bonds 95,959 — 95,959 — Commercial paper 25,194 — 25,194 — U.S. government securities 9,289 — 9,289 — Total marketable securities 130,442 — 130,442 — Total cash equivalents and marketable securities $ 144,351 $ 13,909 $ 130,442 $ — December 31, 2015 Quoted Significant Prices in Other Significant Active Observable Unobservable Markets Inputs Inputs Total (Level 1) (Level 2) (Level 3) (in thousands) Cash equivalents: Money market funds $ 13,231 $ 13,231 $ — $ — U.S. government securities 4,999 — 4,999 — Commercial paper 4,697 — 4,697 — Corporate bonds 3,000 — 3,000 — Total cash equivalents 25,927 13,231 12,696 — Marketable securities: Corporate bonds 125,516 — 125,516 — Commercial paper 19,468 — 19,468 — U.S. government securities 4,500 — 4,500 — Total marketable securities 149,484 — 149,484 — Total cash equivalents and marketable securities $ 175,411 $ 13,231 $ 162,180 $ —
Summary of Marketable Securities	The following tables summarize the Company’s marketable securities as of June 30, 2016 and December 31, 2015: June 30, 2016 Gross Gross Amortized Unrealized Unrealized Cost Gains Losses Fair Value (in thousands) Assets: Corporate bonds (due within 1 year) $ 94,651 $ 19 $ (33 ) $ 94,637 Corporate bonds (due after 1 year through 2 years) 1,317 5 — 1,322 Commercial paper (due within 1 year) 25,199 1 (6 ) 25,194 U.S. government securities (due within 1 year) 9,289 — — 9,289 $ 130,456 $ 25 $ (39 ) $ 130,442 December 31, 2015 Gross Gross Amortized Unrealized Unrealized Cost Gains Losses Fair Value (in thousands) Assets: Corporate bonds (due within 1 year) $ 112,825 $ 1 $ (166 ) $ 112,660 Corporate bonds (due after 1 year through 2 years) 12,884 3 (31 ) 12,856 Commercial paper (due within 1 year) 19,478 — (10 ) 19,468 U.S. government securities (due within 1 year) 4,500 — — 4,500 $ 149,687 $ 4 $ (207 ) $ 149,484

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following as of June 30, 2016 and December 31, 2015: June 30, December 31, 2016 2015 (in thousands) Accrued research and development expenses $ 3,082 $ 3,727 Accrued payroll and related expenses 1,299 1,802 Accrued professional fees 484 422 Accrued other 111 161 $ 4,976 $ 6,112

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Schedule of Notes Payable	As of June 30, 2016 and December 31, 2015, notes payable consist of the following: June 30, December 31, 2016 2015 (in thousands) Notes payable $ 4,680 $ 6,119 Less: current portion (3,057 ) (2,936 ) Notes payable, net of current portion 1,623 3,183 Debt discount, net of accretion (20 ) (36 ) Accretion related to final payment 370 306 Notes payable, net of discount, long term $ 1,973 $ 3,453
Schedule of Estimated Future Principal Payments	As of June 30, 2016, the estimated future principal payments due are as follows: Years Ending December 31, (in thousands) 2016 (July to December) $ 1,497 2017 3,183 Total $ 4,680

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock	The Company recorded stock-based compensation expense related to stock options and restricted common stock in the following expense categories within its consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 (in thousands) (in thousands) Research and development $ 1,002 $ 738 $ 1,830 $ 1,142 General and administrative 1,852 1,201 3,780 1,854 $ 2,854 $ 1,939 $ 5,610 $ 2,996

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Operating Leases	Future minimum lease payments for its operating leases as of June 30, 2016 were as follows: Years Ending December 31, (in thousands) 2016 (July - December) $ 219 2017 300 2018 106 2019 82 $ 707

Nature of the Business and Ba24

Nature of the Business and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jan. 28, 2015USD ($)$ / sharesshares	Dec. 31, 2016Employee	Jun. 30, 2016	Jun. 30, 2015USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Entity incorporation date			Nov. 22, 2005
Proceeds from offering, net of commissions and underwriting discounts				$ 130,044
Underwriting discounts, commissions and offering costs incurred				$ 473
Follow-on Offering [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock issued | shares	3,942,200
Common stock issued price per share | $ / shares	$ 35
Proceeds from offering, net of commissions and underwriting discounts	$ 130,000
Underwriting discounts, commissions and offering costs incurred	$ 500
Scenario, Forecast [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of workforce reduction		34.00%
Estimated number of employees after restructuring | Employee		31

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Summary of Common Stock Equivalents Outstanding (Detail) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of earnings per share	3,986,950	2,503,644
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of earnings per share	3,976,995	2,500,741
Unvested Restricted Common Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of earnings per share	9,955	2,903

Fair Value Measurements and M26

Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 13,909	$ 25,927
Marketable securities	130,442	149,484
Total cash equivalents and marketable securities	144,351	175,411
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	13,909	13,231
U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		4,999
Marketable securities	9,289	4,500
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		3,000
Marketable securities	95,959	125,516
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		4,697
Marketable securities	25,194	19,468
Quoted Prices in Active Markets, (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	13,909	13,231
Total cash equivalents and marketable securities	13,909	13,231
Quoted Prices in Active Markets, (Level 1) [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	13,909	13,231
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		12,696
Marketable securities	130,442	149,484
Total cash equivalents and marketable securities	130,442	162,180
Significant Other Observable Inputs (Level 2) [Member] | U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		4,999
Marketable securities	9,289	4,500
Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		3,000
Marketable securities	95,959	125,516
Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		4,697
Marketable securities	$ 25,194	$ 19,468

Fair Value Measurements and M27

Fair Value Measurements and Marketable Securities - Summary of Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 130,456	$ 149,687
Gross Unrealized Gains	25	4
Gross Unrealized Losses	(39)	(207)
Fair Value	130,442	149,484
Corporate Bonds (Due within 1 Year) [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	94,651	112,825
Gross Unrealized Gains	19	1
Gross Unrealized Losses	(33)	(166)
Fair Value	94,637	112,660
Corporate Bonds (Due After 1 Year Through 2 Years) [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,317	12,884
Gross Unrealized Gains	5	3
Gross Unrealized Losses		(31)
Fair Value	1,322	12,856
Commercial Paper (Due within 1 Year) [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	25,199	19,478
Gross Unrealized Gains	1
Gross Unrealized Losses	(6)	(10)
Fair Value	25,194	19,468
U.S. Government Securities (Due within 1 Year) [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	9,289	4,500
Fair Value	$ 9,289	$ 4,500

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued research and development expenses	$ 3,082	$ 3,727
Accrued payroll and related expenses	1,299	1,802
Accrued professional fees	484	422
Accrued other	111	161
Accrued expenses	$ 4,976	$ 6,112

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - Credit Facility [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Covenants under credit facility			$ 0
Secured Debt [Member]
Debt Instrument [Line Items]
Interest expense on credit facility	$ 100,000	$ 200,000	$ 300,000	$ 400,000
Effective annual interest rate	10.80%		10.80%

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Notes payable	$ 4,680	$ 6,119
Less: current portion	(3,057)	(2,936)
Notes payable, net of current portion	1,623	3,183
Notes payable, net of current portion	1,623	3,183
Notes payable, net of discount, long term	1,973	3,453
Secured Debt [Member] | Credit Facility [Member]
Debt Instrument [Line Items]
Debt discount, net of accretion	(20)	(36)
Accretion related to final payment	$ 370	$ 306

Notes Payable - Schedule of Est

Notes Payable - Schedule of Estimated Future Principal Payments (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Debt Instruments [Abstract]
2016 (July to December)	$ 1,497
2,017	3,183
Total	$ 4,680

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jan. 28, 2015	Jun. 30, 2015
Proceeds from offering, net of commissions and underwriting discounts		$ 130,044
Payments of public offering costs		$ 473
Follow-on Offering [Member]
Common stock issued	3,942,200
Common stock issued price per share	$ 35
Proceeds from offering, net of commissions and underwriting discounts	$ 130,000
Payments of public offering costs	$ 500

Stock-Based Awards - Additional

Stock-Based Awards - Additional Information (Detail) - shares	Jan. 01, 2016	Jun. 30, 2016
Nonemployee Service Based Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of outstanding unvested shares held by nonemployees		9,590
2014 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares added to plan	1,089,700
Shares available for grant		1,270,303

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,854	$ 1,939	$ 5,610	$ 2,996
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,002	738	1,830	1,142
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,852	$ 1,201	$ 3,780	$ 1,854

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Oct. 01, 2015	Mar. 31, 2015Option	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Other Commitments [Line Items]
Operating lease, rental expense			$ 100,000	$ 100,000	$ 200,000	$ 100,000
Subsequent Licensed Product [Member]
Other Commitments [Line Items]
Licensing fees per product maximum			1,300,000		$ 1,300,000
Boston Office Space [Member]
Other Commitments [Line Items]
Lease expiration date					Jul. 31, 2017
Lease extension period					3 years
Additional Boston Office Space [Member]
Other Commitments [Line Items]
Lease expiration date		Jul. 31, 2017
Lease extension period		3 years
Number of options to extend lease | Option		2
San Diego Office Space [Member]
Other Commitments [Line Items]
Lease expiration date	Sep. 30, 2019
Lease extension period	5 years
Maximum [Member] | Pre Commercialization Milestones [Member]
Other Commitments [Line Items]
Milestone payments			12,300,000		$ 12,300,000
Maximum [Member] | Product Commercialization Milestones [Member]
Other Commitments [Line Items]
Milestone payments			$ 12,500,000		$ 12,500,000

Commitments and Contingencies36

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Operating Leases (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2016 (July - December)	$ 219
2,017	300
2,018	106
2,019	82
Total	$ 707

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Defined Contribution Plan Disclosure [Line Items]
Percentage of employer's contribution on employee's base salary			2.00%
Contribution expense			$ 100,000	$ 100,000
Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Contribution expense	$ 100,000	$ 100,000

Australia Research and Develo38

Australia Research and Development Tax Incentive - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Research and Development Tax Incentive [Line Items]
Unrealized foreign currency transaction gains (losses)			$ 108,000	$ (38,000)
Australia [Member]
Research and Development Tax Incentive [Line Items]
Tax incentive receivable	$ 1,700,000		$ 1,700,000		$ 1,300,000
Research and Development [Member]
Research and Development Tax Incentive [Line Items]
Percentage of refundable tax incentive			45.00%
Reduction to research and development expenses	200,000	$ 400,000	$ 300,000	700,000
Research and Development [Member] | Australia [Member]
Research and Development Tax Incentive [Line Items]
Percentage of reduction in research and development costs			45.00%
Other Income [Member] | Maximum [Member]
Research and Development Tax Incentive [Line Items]
Unrealized foreign currency transaction gains (losses)	$ (100,000)	$ (100,000)	$ 100,000	$ (100,000)

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Scenario, Forecast [Member] $ in Millions	5 Months Ended
	Dec. 31, 2016USD ($)Employee
Subsequent Event [Line Items]
Percentage of workforce reduction	34.00%
Estimated number of employees after restructuring | Employee	31
Restructuring charges | $	$ 2.4